Literature DB >> 7658276

Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection.

S Ratnam1, R West, V Gadag.   

Abstract

The effect of concurrent afebrile viral upper respiratory tract infection (URI) on measles and rubella serum antibody response after measles-mumps-rubella (MMR) vaccination was determined in 580 1-year-old children, 369 with URI and 211 without URI, with the use of preimmunization and postimmunization sera. The presence of URI during the preceding 28 days, at the time of, or up to 7 days after immunization had no effect on the antibody response to either the measles or the rubella component of the vaccine. These findings support the recommendation that MMR vaccine be give to children at the recommended age regardless of the presence of afebrile viral URI.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7658276     DOI: 10.1016/s0022-3476(95)70077-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  5 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Can children with minor illnesses be safely immunized?

Authors:  Keswadee Lapphra; David Scheifele
Journal:  Paediatr Child Health       Date:  2011-10       Impact factor: 2.253

3.  Rubella antibody levels in school-aged children in Newfoundland: Implications for a two-dose rubella vaccination strategy.

Authors:  S Ratnam; R West; V Gadag; B Williams; E Oates
Journal:  Can J Infect Dis       Date:  1997-03

Review 4.  Application of pharmacogenomics to vaccines.

Authors:  Gregory A Poland; Inna G Ovsyannikova; Robert M Jacobson
Journal:  Pharmacogenomics       Date:  2009-05       Impact factor: 2.533

Review 5.  Vaccine-induced antibody responses as parameters of the influence of endogenous and environmental factors.

Authors:  H Van Loveren; J G Van Amsterdam; R J Vandebriel; T G Kimman; H C Rümke; P S Steerenberg; J G Vos
Journal:  Environ Health Perspect       Date:  2001-08       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.